Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC dermatology market study

This article was originally published in The Tan Sheet

Executive Summary

The "threat from the herbal medications market" is one of the anticipated restraining factors for the acne medicated products market in the next few years, Frost & Sullivan says in a recently released study on the U.S. OTC dermatology products market. With estimated revenues at $194.78 mil. in 1997, Frost & Sullivan expects the acne products category to grow $249.52 mil. in 2003. The other top "restraints" are increased competition between branded products as well as between branded and generic products, while the top "drivers" for the category are increasing number of teenagers, product diversification and increasing usage rates, the report says. The entire dermatology market, $2.2 bil. in 1997, will reach $2.53 bil. in revenues by 2003, the report notes...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088698

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel